Table 9
Decrease in new CHD according to percentage cholesterol reduction in the cholesterol lowering drug trials versus tryglyceride lowering drug trials (adapted from Durrington et al13)
| Trial | % Cholesterol reduction in trial | % Decrease in new CHD per 1% cholesterol reduction | |
|---|---|---|---|
| *Primary prevention trials. | |||
| Cholesterol (total-LDL) lowering treatment | |||
| Bile acid sequestrant | *LRCCw44 | −11 | 2.2 |
| HMG Co-A reductase inhibitors (statins) | *WOSCOPSw45 | −20 | 1.6 |
| *AFCAPS/TexCAPSw46 | −18 | 2.1 | |
| 4Sw10 | −29 | 1.1 | |
| CAREw11 | −20 | 1.2 | |
| LIPID w12 | −18 | 1.3 | |
| Triglyceride lowering treatment | |||
| Fibrate | *WHOw47 | −9 | 2.2 |
| *Helsinki Heart Studyw48 | −10 | 3.4 | |
| Scandinavian Secondary Prevention Studyw34 | −13 | 3.2 | |
| *SENDCAPw49 | −7 | 9.7 | |
| VA-HITw35 | −4 | 5.5 | |
